切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (05) : 415 -418. doi: 10.3877/cma.j.issn.2095-3232.2017.05.018

所属专题： 文献；

基础研究

siRNA沉默CHI3L1基因对人胆囊癌细胞增殖及侵袭的影响
付亮1, 锁涛2, 李敏2, 宋陆军2,†()   
  1. 1. 200233　上海市第六人民医院心血管外科
    2. 200032　上海，复旦大学附属中山医院普通外科
  • 收稿日期:2017-06-23 出版日期:2017-10-10
  • 通信作者: 宋陆军

Effects of CHI3L1 gene silenced by siRNA on proliferation and invasion of human gallbladder carcinoma cells

Liang Fu1, Tao Suo2, Min Li2, Lujun Song2,†()   

  1. 1. Department of Cardiovascular Surgery, Shanghai Sixth People's Hospital, Shanghai 200233, China
    2. Department of General Surgery, Zhongshan Hospital affiliated to Fudan University, Shanghai 200032, China
  • Received:2017-06-23 Published:2017-10-10
  • Corresponding author: Lujun Song
  • About author:
    Corresponding author: Song Lujun, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

付亮, 锁涛, 李敏, 宋陆军. siRNA沉默CHI3L1基因对人胆囊癌细胞增殖及侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2017, 06(05): 415-418.

Liang Fu, Tao Suo, Min Li, Lujun Song. Effects of CHI3L1 gene silenced by siRNA on proliferation and invasion of human gallbladder carcinoma cells[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(05): 415-418.

目的

探讨siRNA沉默CHI3L1基因对人胆囊癌细胞增殖及侵袭的影响。

方法

采用慢病毒感染和siRNA干扰技术沉默人胆囊癌细胞GBC-SD中CHI3L1基因（siRNA组），同时设立阴性对照组（siRNA-NC组）及空白对照组（GBC-SD组）。采用CCK-8法检测3组细胞吸光度值（A450），Transwell小室细胞迁移和侵袭实验检测穿膜细胞数。3组细胞数据比较采用单因素方差分析和LSD-t检验。

结果

siRNA组24、48、72 h的A450分别为0.87±0.16、0.47±0.21、0.52±0.20，明显低于GBC-SD组的1.20±0.08、1.34±0.15、1.58±0.21（LSD-t=-4.061，-8.483，-7.698；P<0.05）。Transwell小室细胞迁移实验显示siRNA组24 h的穿膜细胞数为（31.0±2.4）个，明显少于GBC-SD组的（92.0±7.2）个（LSD-t=-8.126，P<0.05）。Transwell小室细胞侵袭实验显示siRNA组24 h的穿膜细胞数为（29.0±3.0）个，明显少于GBC-SD组的（76.0±5.2）个（LSD-t=-7.883，P<0.05）。

结论

siRNA沉默CHI3L1基因后可明显抑制人胆囊癌细胞增殖、迁移和侵袭能力。

关键词: 胆囊肿瘤, RNA，小分子干扰, 肿瘤侵润, 细胞迁移分析
Objective

To investigate the effects of CHI3L1 gene silenced by siRNA upon the proliferation and invasion of human gallbladder carcinoma cells.

Methods

The CHI3L1 gene of the human gallbladder carcinoma cell GBC-SD was silenced by slow-virus infection and siRNA interference technique (siRNA group). And negative control group (siRNA-NC group) and blank control group (GBC-SD group) were established. The cell absorbance values (A450) among three groups were detected by CCK-8 assay. The quantity of membrane-penetrating cells was detected by Transwell cell migration and invasion assays. The cellular data among three groups were compared by one-way analysis of variance and LSD-t test.

Results

The A450 at 24, 48, 72 h in the siRNA group was respectively 0.87±0.16, 0.47±0.21 and 0.52±0.20, significantly lower than 1.20±0.08, 1.34±0.15 and 1.58±0.21 in the GBC-SD group (LSD-t=-4.061, -8.483, -7.698; P<0.05). Transwell cell migration assay revealed that, the quantity of membrane-penetrating cells at 24 h in the siRNA group was 31.0±2.4, significantly less than 92.0±7.2 in the GBC-SD group (LSD-t=-8.126, P<0.05). Transwell cell invasion assay revealed that, the quantity of membrane-penetrating cells at 24 h in the siRNA group was 29.0±3.0, significantly less than 76.0±5.2 in the GBC-SD group (LSD-t=-7.883, P<0.05).

Conclusions

CHI3L1 gene silenced by siRNA can significantly inhibit the proliferation, migration and invasion capabilities of human gallbladder carcinoma cells.

Key words: Gallbladder neoplasms, RNA, small interfering, Neoplasm invasiveness, Cell migration assays
图1 Western blot检测siRNA对CHI3L1蛋白表达的抑制作用
图2 CCK-8法检测细胞生长曲线
图3 Transwell小室细胞迁移实验检测穿膜细胞数
[1]
Rakić M, Patrlj L, Kopljar M, et al. Gallbladder cancer[J]. Hepatobiliary Surg Nutr, 2014, 3(5):221-226.
[2]
Zhang JT, Sun W, Zhang WZ, et al. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway[J]. BMC Cancer, 2014, 14:193.
[3]
Li M, Zhang F, Wang X, et al. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway[J]. Cancer Sci, 2015, 106(10):1341-1350.
[4]
Thöm I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer[J]. Cancer, 2010, 116(17):4114-4121.
[5]
Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas[J]. Int J Clin Exp Pathol, 2010, 3(3):226-237.
[6]
Pan JJ, Ge YS, Xu GL, et al. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(6):1043-1054.
[7]
Libreros S, Garcia-Areas R, Shibata Y, et al. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model[J]. Int J Cancer, 2012, 131(2):377-386.
[8]
Shao R, Cao QJ, Arenas RB, et al. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers[J]. Br J Cancer, 2011, 105(8):1203-1209.
[9]
Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker?[J]. Future Oncol, 2009, 5(7):1065-1082.
[10]
付亮，锁涛，张钰，等．几丁质酶-3样蛋白-1在胆囊癌组织中的表达及其临床意义[J]．中华实验外科杂志，2014，31(5):1114-1116.
[11]
Kawada M, Seno H, Kanda K, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer[J]. Oncogene, 2012, 31(26):3111-3123.
[12]
Barone C, Basso M, Biolato M, et al. A phase II study of sunitinib in advanced hepatocellular carcinoma[J]. Dig Liver Dis, 2013, 45(8):692-698.
[13]
Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma[J]. World J Gastroenterol, 2016, 22(4):1335-1347.
[14]
Stec WJ, Rosiak K, Siejka P, et al. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes[J]. Oncotarget, 2016, 7(22): 31907-31925.
[15]
Sharma KL, Rai R, Srivastava A, et al. A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition[J]. Tumor Biol, 2014, 35(9): 8597-8606.
[16]
Sharma KL, Misra S, Kumar A, et al. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer[J]. Liver Int, 2012, 32(8):1278-1286.
[17]
陈洁盈，陈耀庭，林泽宇，等．三氧化二砷逆转低浓度索拉非尼对人肝癌细胞促迁移作用及其机制[J/CD]．中华肝脏外科手术学电子杂志，2016，5(2):114-118.
[18]
Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered[J]. FEBS J, 2013, 280(21): 5350-5370.
[1] 舒斌, 朱君佑, 祁少海. 色素上皮衍生因子在创面中的表达变化及对人真皮微血管内皮细胞的作用与机制[J]. 中华损伤与修复杂志(电子版), 2021, 16(04): 301-309.
[2] 闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J]. 中华普通外科学文献(电子版), 2023, 17(05): 391-394.
[3] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[4] 李永宁, 付雪芹, 李英, 刘鹏, 刘松柏, 潘耀振. 基因相似序列家族成员126A靶向调控波形蛋白促进胰腺癌细胞侵袭和迁移及其机制[J]. 中华普外科手术学杂志(电子版), 2023, 17(02): 139-144.
[5] 储涛, 董晓, 邵荣金, 陈胜东, 吕旭, 龚伟达. 腹腔镜根治术治疗原发性胆囊癌的近期疗效及生存分析[J]. 中华普外科手术学杂志(电子版), 2021, 15(03): 343-346.
[6] 田广磊, 侯梅华, 李智德, 余波锋, 马俊杰, 李婷婷, 王春, 陈伦牮, 陈雄. 胆囊结石合并混合性神经内分泌-非神经内分泌肿瘤一例报告[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 342-344.
[7] 谭涛, 胡志刚, 周兵海, 吴华俊, 余新, 袁荣发, 邹书兵, 王恺. 胆囊癌根治性切除术后复发影响因素及列线图预测模型构建[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 179-184.
[8] 付佳禄, 张景玮, 金哲川, 张东, 耿智敏. 胆囊癌临床分型的合理性及其与预后关系——单中心486例分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 173-178.
[9] 张东, 耿智敏, 全志伟. 胆囊癌临床分型研究现状及进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 147-152.
[10] 杨新伟, 杨平华, 闫兴州, 邢相磊, 刘虎, 赵永洋, 张克诚, 张宝华. 胆囊癌肝切除范围再认识[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 142-146.
[11] 王坚, 杨传鑫. 胆囊癌外科规范治疗的难点与焦点[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 137-141.
[12] 魏志鸿, 郭娟, 江哲龙, 江艺, 吕立志. miR-4458靶向结合BZW2对肝癌细胞增殖、迁移和侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(01): 108-113.
[13] 邬杰忠, 柯春连, 陈少宏, 刘波, 姚志成. circZKSCAN1抑制肝癌细胞侵袭转移的机制[J]. 中华肝脏外科手术学电子杂志, 2022, 11(01): 92-97.
[14] 朱倩, 陈怡然, 侍超, 沈晶尧, 徐亮, 应杰, 胡立平. miR-429在胰腺导管腺癌患者预后中的价值及作用机制[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 629-635.
[15] 胡明泰, 郑玉廷, 谢峰. 胆囊癌病因及分子机制研究进展[J]. 中华肝脏外科手术学电子杂志, 2021, 10(02): 224-226.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号